June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Factors Predicting Treatment Frequency of Ranibizumab Injections during the Second Year in Diabetic Macular Edema
Author Affiliations & Notes
  • Tomoaki Murakami
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Keiichi Nishikawa
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Akihito Uji
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Yoko Dodo
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Noriko Terada
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Nao Aisu
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Akitaka Tsujikawa
    Ophthalomogy and visual sciences, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Tomoaki Murakami, Novartis (F); Keiichi Nishikawa, None; Akihito Uji, None; Yoko Dodo, None; Noriko Terada, None; Nao Aisu, None; Akitaka Tsujikawa, Bayer (F), Novartis (F)
  • Footnotes
    Support  Grant-in-Aid for the Scientific Research of Japan Society for the Promotion of Science (20K09788)
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1067. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tomoaki Murakami, Keiichi Nishikawa, Akihito Uji, Yoko Dodo, Noriko Terada, Nao Aisu, Akitaka Tsujikawa; Factors Predicting Treatment Frequency of Ranibizumab Injections during the Second Year in Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1067.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Anti-VEGF therapy is the first-line for diabetic macular edema (DME), although its socioeconomic burden is a serious concern. We therefore investigate the predictors of the treatment frequency in the second year under as-needed intravitreal ranibizumab (IVR) injections for DME.

Methods : In this retrospective study, we reviewed 65 eyes of 60 patients with center-involved DME who received pro re nata (PRN) IVR injections following three monthly loading doses. The central subfield thickness (CST) and qualitative findings were assessed on spectral domain optical coherence tomography (SD-OCT) images. We then investigated whether parameters at baseline or 12-month visit were associated with the treatment frequency in the second year.

Results : The number of ranibizumab injections decreased from 6 (4-8) during the first year to 2 (0-3) during the second year (P<0.001), despite the maintenance of functional efficacy from 12- to 24-month visits. The injection numbers during the first year (ρ=0.259, P=0.037) but not during the second year (ρ=0.152, P=0.226) were modestly related to logarithm of the minimum angle of resolution (logMAR) improvement at 24 months. Multivariate analyses revealed that CST and hyperreflective walls in foveal cystoid spaces at baseline were associated with the number of IVR injections during the second year (β=0.363, P=0.003 and β=0.234, P=0.048, respectively). The treatment frequency during the second year was also related with CST (β=0.266, P=0.012), hyperreflective walls (β=0.394, P=0.002), and the cumulative doses of ranibizumab injections (β=0.294, P=0.006) at 12-month visit.

Conclusions : CST and hyperreflective walls in foveal cystoid spaces are designated as predictors of treatment frequency of ranibizumab injections during the second year in DME.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×